A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript
PURPOSE: In a preclinical drug screen, mithramycin was identified as a potent inhibitor of the Ewing sarcoma EWS-FLI1 transcription factor. We conducted a phase I/II trial to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of mithramycin in children with refractory solid tumors, and the activity in children and adults with refractory Ewing sarcoma.
PATIENTS AND METHODS: Mithramycin was administered intravenously over 6 h once daily for 7 days for 28 day cycles. Adult patients (phase II) initially received mithramycin at the previously determined recommended dose of 25 µg/kg/dose. The planned starting dose for children (phase I) was 17.5 µg/kg/dose. Plasma samples were obtained for mithramycin PK analysis.
RESULTS: The first two adult patients experienced reversible grade 4 alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation exceeding the MTD. Subsequent adult patients received mithramycin at 17.5 µg/kg/dose, and children at 13 µg/kg/dose with dexamethasone pretreatment. None of the four subsequent adult and two pediatric patients experienced cycle 1 DLT. No clinical responses were observed. The average maximal mithramycin plasma concentration in four patients was 17.8 ± 4.6 ng/mL. This is substantially below the sustained mithramycin concentrations ≥50 nmol/L required to suppress EWS-FLI1 transcriptional activity in preclinical studies. Due to inability to safely achieve the desired mithramycin exposure, the trial was closed to enrollment.
CONCLUSIONS: Hepatotoxicity precluded the administration of a mithramycin at a dose required to inhibit EWS-FLI1. Evaluation of mithramycin in patients selected for decreased susceptibility to elevated transaminases may allow for improved drug exposure.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
---|---|
Enthalten in: |
Cancer chemotherapy and pharmacology - 80(2017), 3 vom: 23. Sept., Seite 645-652 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Grohar, Patrick J [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 27.12.2017 Date Revised 25.02.2020 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s00280-017-3382-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM274102374 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM274102374 | ||
003 | DE-627 | ||
005 | 20231225002729.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2017 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00280-017-3382-x |2 doi | |
028 | 5 | 2 | |a pubmed24n0913.xml |
035 | |a (DE-627)NLM274102374 | ||
035 | |a (NLM)28735378 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Grohar, Patrick J |e verfasserin |4 aut | |
245 | 1 | 2 | |a A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.12.2017 | ||
500 | |a Date Revised 25.02.2020 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a PURPOSE: In a preclinical drug screen, mithramycin was identified as a potent inhibitor of the Ewing sarcoma EWS-FLI1 transcription factor. We conducted a phase I/II trial to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics (PK) of mithramycin in children with refractory solid tumors, and the activity in children and adults with refractory Ewing sarcoma | ||
520 | |a PATIENTS AND METHODS: Mithramycin was administered intravenously over 6 h once daily for 7 days for 28 day cycles. Adult patients (phase II) initially received mithramycin at the previously determined recommended dose of 25 µg/kg/dose. The planned starting dose for children (phase I) was 17.5 µg/kg/dose. Plasma samples were obtained for mithramycin PK analysis | ||
520 | |a RESULTS: The first two adult patients experienced reversible grade 4 alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation exceeding the MTD. Subsequent adult patients received mithramycin at 17.5 µg/kg/dose, and children at 13 µg/kg/dose with dexamethasone pretreatment. None of the four subsequent adult and two pediatric patients experienced cycle 1 DLT. No clinical responses were observed. The average maximal mithramycin plasma concentration in four patients was 17.8 ± 4.6 ng/mL. This is substantially below the sustained mithramycin concentrations ≥50 nmol/L required to suppress EWS-FLI1 transcriptional activity in preclinical studies. Due to inability to safely achieve the desired mithramycin exposure, the trial was closed to enrollment | ||
520 | |a CONCLUSIONS: Hepatotoxicity precluded the administration of a mithramycin at a dose required to inhibit EWS-FLI1. Evaluation of mithramycin in patients selected for decreased susceptibility to elevated transaminases may allow for improved drug exposure | ||
650 | 4 | |a Clinical Trial, Phase I | |
650 | 4 | |a Clinical Trial, Phase II | |
650 | 4 | |a Journal Article | |
650 | 4 | |a EWS–FLI1 | |
650 | 4 | |a Ewing sarcoma | |
650 | 4 | |a Mithramycin | |
650 | 7 | |a Antibiotics, Antineoplastic |2 NLM | |
650 | 7 | |a EWS-FLI fusion protein |2 NLM | |
650 | 7 | |a Oncogene Proteins, Fusion |2 NLM | |
650 | 7 | |a Proto-Oncogene Protein c-fli-1 |2 NLM | |
650 | 7 | |a RNA-Binding Protein EWS |2 NLM | |
650 | 7 | |a Plicamycin |2 NLM | |
650 | 7 | |a NIJ123W41V |2 NLM | |
700 | 1 | |a Glod, John |e verfasserin |4 aut | |
700 | 1 | |a Peer, Cody J |e verfasserin |4 aut | |
700 | 1 | |a Sissung, Tristan M |e verfasserin |4 aut | |
700 | 1 | |a Arnaldez, Fernanda I |e verfasserin |4 aut | |
700 | 1 | |a Long, Lauren |e verfasserin |4 aut | |
700 | 1 | |a Figg, William D |e verfasserin |4 aut | |
700 | 1 | |a Whitcomb, Patricia |e verfasserin |4 aut | |
700 | 1 | |a Helman, Lee J |e verfasserin |4 aut | |
700 | 1 | |a Widemann, Brigitte C |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer chemotherapy and pharmacology |d 1990 |g 80(2017), 3 vom: 23. Sept., Seite 645-652 |w (DE-627)NLM00036438X |x 1432-0843 |7 nnns |
773 | 1 | 8 | |g volume:80 |g year:2017 |g number:3 |g day:23 |g month:09 |g pages:645-652 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00280-017-3382-x |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 80 |j 2017 |e 3 |b 23 |c 09 |h 645-652 |